Date: 2016-11-03
Type of information: Series B financing round
Company: NBE Therapeutics (Switzerland)
Investors: PPF Group (Czech Republic) Boehringer Ingelheim Venture Fund (BIVF) (Germany) existing private investors and a new private investor
Amount: CHF 20 million (€ 18.5 million)
Funding type: series B financing round
Planned used: NBE develops next-generation antibody drug conjugate (ADC) products with the potential to improve the outcome for cancer patients, as it continues to develop ADCs based on its Transpo-mAb™ antibody platform, site-specific SMACTM conjugation technology and novel ultra-potent toxin platform. The funds will enable NBE to advance the lead product of its ADC pipeline to the end of phase I/II clinical trials and further develop its cutting-edge platforms.
Others: * On November 3, 2016, NBE Therapeutics, a biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, announced closing of a CHF 20 million Series B financing round. PPF Group led the round with participation from Boehringer Ingelheim Venture Fund, all other existing private investors and a new private investor. As part of the transaction, Dr. Jens Hennecke, CBO of Sotio, has joined the board of directors of NBE. Sotio is an international biotechnology company developing therapies for the treatment of cancer. As a member of PPF Group, Sotio is spearheading PPF’s investment and partnering activities in the biotechnology sector.
Therapeutic area:
